Lomako Wieslawa M, Lomako Joseph, Soto Pedro, Carraway Coralie A Carothers, Carraway Kermit L
Department of Cell Biology and Anatomy, University of Miami Miller School of Medicine, Florida 33136, USA.
J Cell Biochem. 2009 Jul 1;107(4):797-802. doi: 10.1002/jcb.22177.
Muc4 is a heterodimeric membrane mucin implicated in epithelial differentiation and tumor progression. It is expressed from a single gene as a 300 kDa precursor protein which is cleaved in the endoplasmic reticulum to its two subunits. Our previous work has shown that Muc4 is regulated by TGFbeta, which represses the precursor cleavage. Working with Muc4-transfected A375 tumor cells, we now show that Muc4 undergoes proteosomal degradation. Proteosome inhibitors prolong the life of the precursor, shunt the Muc4 into cytoplasmic aggresomes, increase the level of Muc4 associated with the endoplasmic reticulum chaperones calnexin and calreticulin and increase the levels of ubiquitinated Muc4. Most importantly, proteosome inhibitors repress the TGFbeta inhibition of Muc4 expression. These results suggest a model in which TGFbeta inhibits precursor cleavage, shunting the precursor into the proteosomal degradation pathway. Thus, the cells have evolved a mechanism to use the quality control pathway for glycoproteins to control the quantity of the protein produced.
Muc4是一种异二聚体膜黏蛋白,与上皮分化和肿瘤进展有关。它由单个基因表达为一种300 kDa的前体蛋白,该前体蛋白在内质网中被切割成两个亚基。我们之前的工作表明,Muc4受转化生长因子β(TGFβ)调控,TGFβ会抑制前体的切割。通过对转染Muc4的A375肿瘤细胞进行研究,我们现在发现Muc4会经历蛋白酶体降解。蛋白酶体抑制剂可延长前体的寿命,使Muc4进入细胞质聚集体,增加与内质网伴侣钙连蛋白和钙网蛋白相关的Muc4水平,并增加泛素化Muc4的水平。最重要的是,蛋白酶体抑制剂可抑制TGFβ对Muc4表达的抑制作用。这些结果提示了一种模型,即TGFβ抑制前体切割,将前体分流至蛋白酶体降解途径。因此,细胞进化出了一种机制,利用糖蛋白的质量控制途径来控制所产生蛋白质的数量。